Morbidity Rate

In insurance, the morbidity rate refers to the frequency of illness or disease within a particular population. More specifically, it is the rate at which individuals within a specific group become ill or develop a particular disease over a given period of time. The morbidity rate is an important factor in determining insurance rates and policies.

Here are some key features of morbidity rate:

• The morbidity rate is calculated by dividing the number of people who have developed a particular disease or illness by the total number of people in the population being studied.

• The morbidity rate is typically expressed as a percentage or a rate per 1,000 or 100,000 individuals.

• The morbidity rate can be influenced by a variety of factors, including age, gender, lifestyle, and environmental factors.

• Insurers use morbidity rates to help determine premiums and to assess the risk of providing coverage to a particular group of individuals.

• Morbidity rates can also be used to identify patterns of disease and to help develop strategies for prevention and treatment.

For example, an insurance company might use morbidity rates to assess the risk of providing coverage for a particular group of individuals, such as smokers or individuals with a history of heart disease. If the morbidity rate for a particular group is high, the insurer may charge higher premiums or offer less coverage to mitigate their risk. Similarly, public health officials may use morbidity rates to identify areas where a particular disease is more prevalent and to develop strategies for prevention and treatment.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.